Madrigal (NASDAQ: MDGL) insider files to sell 263 vested shares

Rhea-AI Filing Summary

Madrigal Pharmaceuticals insider files to sell common stock. A Form 144 notice indicates an intention to sell 263 shares of Madrigal Pharmaceuticals common stock through Morgan Stanley Smith Barney LLC on or about 01/20/2026 on the Nasdaq Stock Market. These shares were acquired on 01/16/2026 via a restricted stock unit grant that vested on the same date. The filing notes that Madrigal Pharmaceuticals had 22,711,420 shares of common stock outstanding. Over the past three months, the same seller disposed of 429 shares of common stock on 01/20/2026 for gross proceeds of 215100.6. The signer represents that they are not aware of undisclosed material adverse information about the company.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza, 8th Floor New York NY 10004	263	131941.84	22711420	01/20/2026	Nasdaq Stock Market

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/16/2026	Restricted Stock Unit Grant	Issuer			263	01/16/2026	Vesting of Restricted Stock Units

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Shannon Kelley c/o Madrigal Pharmaceuticals, Inc. 200 Barr Harbor Drive, Suite 200 West Conshohocken PA 19428	Common Stock	01/20/2026	429	215100.6

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the MDGL Form 144 filing disclose?

The Form 144 filing discloses an intention to sell 263 shares of Madrigal Pharmaceuticals common stock through Morgan Stanley Smith Barney LLC on or about 01/20/2026 on the Nasdaq Stock Market.

How were the MDGL shares being sold acquired?

The 263 shares to be sold were acquired as a restricted stock unit grant from the issuer, which vested on 01/16/2026, the same date they were acquired.

How many Madrigal Pharmaceuticals shares are outstanding?

The Form 144 states that Madrigal Pharmaceuticals had 22,711,420 shares of common stock outstanding.

Were there other recent MDGL share sales by this seller?

Yes. The filing reports that the same seller disposed of 429 shares of Madrigal Pharmaceuticals common stock on 01/20/2026 for gross proceeds of 215100.6.

Who is the seller in this MDGL Form 144 filing?

The section on prior sales identifies the seller as Shannon Kelley, care of Madrigal Pharmaceuticals, Inc., at its West Conshohocken, Pennsylvania address.

What representation does the seller make about MDGL in the Form 144?

The person on whose account the securities are to be sold represents that they do not know of any material adverse information about Madrigal Pharmaceuticals’ current or prospective operations that has not been publicly disclosed.